- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.BioPharma Dive · 18d ago↗ source
- FDA quietly pushes back deadline on electric shock banMassachusetts' biggest nursing strike ever, tackling the male loneliness epidemic, and other health news for Morning RoundsSTAT · 18d ago↗ source
- The data that led Cellular Intelligence to pick up Novo's Parkinson's stem cell therapyMONTREAL — After Novo Nordisk closed its cell therapy unit, Cellular Intelligence contracted neurologist and drug developer Nuno Mendonça to conduct due diligence on the Danish pharma’s Parkinson’s…